STOCK TITAN
  1. Home
  2. News
  3. ENSC

Ensysce Biosciences, Inc. - ENSC STOCK NEWS

Welcome to our dedicated page for Ensysce Biosciences news (Ticker: ENSC), a resource for investors and traders seeking the latest updates and insights on Ensysce Biosciences stock.

Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a San Diego-based clinical-stage biotech company specializing in the development of safer prescription drugs using its proprietary technology platforms. The company focuses on creating new, tamper-proof opioids that aim to reduce drug abuse and prevent overdoses. Ensysce leverages its Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms to develop innovative pain relief options with a lower risk of misuse.

The company’s core projects include two key drug platforms: the TAAP technology, which activates upon ingestion to release pain medication, and the MPAR technology, designed to prevent overdose by inhibiting further release of the drug when excess doses are consumed. These platforms are supported by global intellectual property protection, ensuring a wide array of prescription drug compositions.

Recent milestones include the FDA’s Breakthrough Therapy designation for PF614-MPAR, a combination product designed to provide overdose protection alongside effective pain relief. This designation accelerates the drug’s development and review process, highlighting its potential to offer substantial improvements over existing therapies. Ensysce’s lead candidate, PF614, is currently in Phase 3 clinical development, having demonstrated efficacy and safety in previous trials.

In terms of financial health, Ensysce has shown stability, with recent funding from federal grants and warrant exercises supporting ongoing research and development. The company's collaboration with Quotient Sciences aims to further optimize their PF614-MPAR drug product, enhancing its effectiveness and safety profile.

Ensysce is also expanding its product pipeline to address opioid use disorder (OUD) with PF9001, a TAAP-based candidate that has shown promise in reducing cardiovascular side effects compared to traditional treatments. Supported by a multi-year HEAL grant from the NIH and NIDA, this candidate is poised to enter human clinical studies within the next 12 to 18 months.

For more detailed information about Ensysce Biosciences, Inc. and its innovative projects, please visit www.ensysce.com.

News

Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published

Rhea-AI Summary
Ensysce Biosciences, a clinical stage pharmaceutical company (NASDAQ: ENSC), presented at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference. The webcast discussed the Company's innovative solutions for pain relief with reduced opioid abuse risk. CEO Dr. Lynn Kirkpatrick highlighted TAAP and MPAR technology, lead drug candidates PF614 and PF614-MPAR, FDA Breakthrough Therapy designation for PF614-MPAR, and upcoming milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
none
-
News

Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

Rhea-AI Summary
Ensysce Biosciences, Inc. (ENSC) announces participation in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference. The company focuses on developing innovative solutions for severe pain relief while reducing opioid misuse. Dr. Lynn Kirkpatrick and Dave Humphrey will present at the conference, offering a Q&A session. Attendees can register for the event for free and access the webcast later. Ensysce's management team will also be available for one-on-one meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News

Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary
Ensysce Biosciences, Inc. reports financial results for Q4 and full year 2023, discusses FDA Breakthrough Therapy Designation, Phase 3 plans, and updates on TAAP and MPAR programs. The Company's CEO highlights progress in clinical studies and regulatory approvals, emphasizing the potential of their innovative opioid products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.87%
Tags
earnings
News

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

Rhea-AI Summary
Ensysce Biosciences, Inc. (NASDAQ:ENSC) receives extension from Nasdaq to demonstrate compliance with equity requirement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
none
-
News

Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection

Rhea-AI Summary
Ensysce Biosciences, Inc. (NASDAQ:ENSC) receives FDA guidance for its PF614-MPAR program, a 'Next Generation' opioid analgesic with overdose protection. The FDA provided feedback on non-clinical studies required for NDA submission and approval, streamlining development plans. PF614-MPAR, granted Breakthrough Therapy designation, aims to provide sustained pain relief with reduced adverse effects and overdose protection. Ensysce's lead drug candidate, PF614, has entered Phase 3 clinical development, demonstrating efficacy and safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.11%
Tags
none
-
News

Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript

Rhea-AI Summary
Ensysce Biosciences, Inc. announces positive results from the clinical study PF614-102 comparing PF614, a novel TAAP prodrug of oxycodone, to OxyContin. The study demonstrates a clear dose relationship between PF614 and oxycodone, achieving bioequivalence with OxyContin. PF614 offers advantages such as similar oxycodone exposures in fasted and fed states, a longer half-life, and potential as a twice-daily pain treatment. The manuscript published in Clinical and Translational Science highlights the safety and pharmacokinetics profile of PF614, positioning it as a promising analgesic for severe pain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
none
News

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Rhea-AI Summary
Ensysce Biosciences, Inc. (ENSC) announces the immediate exercise of warrants to purchase 3,601,752 shares of common stock at a reduced price, expecting gross proceeds of approximately $4.7 million. H.C. Wainwright & Co. acts as the exclusive placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.56%
Tags
none
-
News

Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference

Rhea-AI Summary
Ensysce Biosciences, Inc. (NASDAQ:ENSC) announced that their PF614-MPAR has been recognized as a potential medical breakthrough and was selected to present one of the top 12 best Flash Talks at the 2024 American Association of Pain Medicine (AAPM) Meeting. The company's novel PF614-MPAR is designed to provide optimal pain relief at prescribed doses yet limit accidental or intentional overdose by 'shutting down' opioid release if too much active drug is consumed. PF614-MPAR was granted Breakthrough Therapy designation by the FDA, recognizing its innovative approach to preventing prescription opioid overdoses. Ensysce's CEO and Chief Medical Officer expressed their enthusiasm and confidence in the potential of PF614-MPAR and its ability to disrupt the opioid market while mitigating the risk of overdose.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6%
Tags
conferences
-
News

Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain

Rhea-AI Summary
Ensysce Biosciences, Inc. announces successful completion of End of Phase 2 meeting with FDA regarding its lead analgesic, PF614. The meeting facilitated affirmation of non-clinical program and constructive ideas exchange for Phase 3 trial designs. Clinical data shows PF614 is bioequivalent to OxyContin with a longer half-life, lower abuse potential, and significant analgesic activity. Phase 3 trials expected to begin in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.5%
Tags
clinical trial
News

Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting

Rhea-AI Summary
Ensysce Biosciences, Inc. announces the presentation of their lead product, PF614-MPAR, at the NIH HEAL Initiative Scientific Meeting. The drug has been granted Breakthrough Therapy Designation by the FDA and has received funding from NIDA. The company aims to combat abuse and protect against oral opioid overdose, addressing the current opioid crisis. The presentation of the trial data reflects the successful optimization of the drug product, with potential to become a first-in-class 'Next Generation' opioid with abuse deterrent and oral overdose protection properties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.78%
Tags
conferences

FAQ

What is the current stock price of Ensysce Biosciences (ENSC)?

The current stock price of Ensysce Biosciences (ENSC) is $0.65 as of November 1, 2024.

What is the market cap of Ensysce Biosciences (ENSC)?

The market cap of Ensysce Biosciences (ENSC) is approximately 9.7M.

What is Ensysce Biosciences, Inc.?

Ensysce Biosciences, Inc. is a clinical-stage biotech company in San Diego focused on developing safer prescription drugs using proprietary abuse deterrent and overdose protection technologies.

What technologies does Ensysce use in its drug development?

Ensysce employs its proprietary Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) technologies to create tamper-proof drugs that minimize the risk of abuse and overdose.

What are the core products in Ensysce’s development pipeline?

The core products include PF614, an extended-release oxycodone utilizing TAAP technology, and PF614-MPAR, which combines overdose protection with effective pain relief.

What recent achievements have Ensysce made?

Ensysce has received Breakthrough Therapy designation from the FDA for PF614-MPAR, highlighting the product's potential to improve pain management while preventing overdoses.

What is the significance of FDA Breakthrough Therapy designation?

The Breakthrough Therapy designation expedites the development and review process for drugs that show substantial improvement over existing therapies, facilitating faster access to patients.

How is Ensysce addressing the opioid epidemic?

Ensysce is developing tamper-proof opioids that reduce the risk of abuse and overdose, with products like PF614-MPAR designed to prevent the release of excess doses and provide safer pain management options.

What financial strategies support Ensysce’s operations?

Ensysce’s financial health is bolstered by federal grants and warrant exercises, which help fund its ongoing research and development efforts.

What partnerships has Ensysce formed to advance its drug development?

Ensysce collaborates with Quotient Sciences to optimize and test its drug products, enhancing their safety and effectiveness through innovative translational pharmaceutics processes.

What future projects is Ensysce Biosciences involved in?

Ensysce is expanding its pipeline to include PF9001 for opioid use disorder (OUD), supported by significant funding from the NIH and NIDA to move into human clinical studies.

Where can more information about Ensysce Biosciences be found?

Additional details about Ensysce Biosciences can be found on their official website at www.ensysce.com.

Stock ENSC logo
Ensysce Biosciences, Inc.

Nasdaq:ENSC

ENSC Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

ENSC Stock Data

9.69M
14.91M
1.17%
3.35%
0.82%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
LA JOLLA